Meet Our Immunology Leadership Team
DAVID M. LEE, M.D., Ph.D.
GLOBAL THERAPEUTIC AREA HEAD
David M. Lee, M.D., Ph.D., is Global Immunology Therapeutic Area Head for the Janssen Pharmaceutical Companies of Johnson & Johnson where he leads a team focused on end-to-end pipeline and a portfolio of treatments for immune-mediated disease. Under his leadership, Immunology researchers are working to build on the success of our current portfolio, which includes STELARA® (ustekinumab) and TREMFYA® (guselkumab).
Prior to joining Johnson & Johnson in September 2018, David was based in Basel, Switzerland, where he served as Global Head, Immunology, Inflammation and Infectious Disease Discovery and Translation Area for Roche, and prior to that, as Global Head of Autoimmunity, Dermatology, and Transplant Translational Medicine at the Novartis Institutes for BioMedical Research. In each of these roles, he led on the strategic approaches that fed those companies’ pipelines, prioritized assets, and accelerated their development. His ability to develop external collaborations and to lead and develop his teams was central to his success in each organization.
Before transitioning to the pharmaceutical industry, David was a faculty member at Brigham and Women’s Hospital/Harvard Medical School. While there, his research laboratory focused on disease mechanisms in Rheumatology and he also practiced Rheumatology. As a precursor to his career in industry, while at Harvard, he also participated in co-founding multiple start-ups. Ultimately, one – a biotech – was acquired by a major pharmaceutical company.
He is an active author and speaker, having completed more than 80 peer-reviewed publications and book chapters, and more than 100 lectures/seminars.
David earned his undergraduate degree at Stanford University, where he discovered his fascination with the intricacies of the immune system. He subsequently earned his M.D. and Ph.D. in Microbiology/Immunology from the Duke University School of Medicine. His passion for developing new medicines is rooted in his experiences treating patients as a practicing rheumatologist.
David M. Lee, M.D., Ph.D.
Global Therapeutic Area Head
TERI L. LAWVER
GLOBAL COMMERCIAL STRATEGY LEADER
Teri Lawver is the Global Commercial Strategy Leader, Global Vice President, for the Immunology Therapeutic Area with Janssen Pharmaceutical Companies of Johnson & Johnson. Together with the Immunology R&D Therapeutic Area leader, she has end-to-end responsibility for the Janssen Immunology portfolio and pipeline.
Teri has more than 25 years of global healthcare and business leadership experience spanning three continents, three healthcare sectors, and dozens of disease areas. Since joining Johnson & Johnson in 2002 at Centocor, Teri has held several leadership and executive positions across the Johnson & Johnson Family of Companies. She is a values-driven leader who has delivered above-market performance in each of the five Johnson & Johnson business units she has led. Prior to joining Johnson & Johnson, Teri was an Associate Principal at McKinsey & Company and a leader in the Firm’s Global Healthcare practice. She began her career as a Derivatives Analyst at Bloomberg Financial Markets, LLP.
A multi-faceted leader, Teri is adept at delivering both transformational strategies and operational excellence. She is a vocal champion of diversity and inclusion, and has a proven track record of building new businesses, creating sustainable innovation-based growth, identifying exceptional talent, and developing high-performance teams.
Teri holds a Bachelor of Science degree, summa cum laude, from Georgetown University in Washington D.C., and an MBA from Duke University in Durham, North Carolina.
Teri L. Lawver
Global Commercial Strategy Leader
DISEASE AREA COMMERCIAL LEADER
GASTROENTEROLOGY & IL-23 PATHWAY
Richard Appiah is Vice President, Disease Area Commercial Leader Gastroenterology & IL-23 Pathway for the Immunology Therapeutic Area at Janssen Global Services. In this role, he is responsible for leading the commercial strategy to support the discovery, development, and launch of new therapeutics within the inflammatory bowel disease and IL-23 pathway areas.
Prior to this role, Richard served as Senior Director, Franchise Strategy Marketing for the U.S. Cardiovascular & Metabolism organization at Janssen, significantly contributing to growth of the XARELTO® brand. Under his leadership, XARELTO established a first-of-its-kind, direct-to-patient commercial model designed to improve adherence and lower patients’ out-of-pocket cost. Richard joined Johnson & Johnson in 2002 and has held roles of increasing responsibility in Janssen Oncology, Neuroscience, and Immunology.
Beyond his work at Johnson & Johnson, Richard spent four years at Pfizer in the Specialty business unit where he was responsible for payer marketing and contracting strategies for a portfolio of biologic products.
Richard holds Bachelor and Master of Science degrees from Syracuse University and a Master of Business Administration degree from Harvard Business School.
Disease Area Commercial Leader
Gastroenterology & IL-23 Pathway
DISEASE AREA COMMERCIAL LEADER
Jennifer Beachell is Vice President, Disease Area Commercial Leader, Autoantibody, within the Immunology Therapeutic Area (TA) at Janssen Global Services. In this role, Jen is responsible for developing and executing the commercial strategy to support the discovery, development, and launch of new therapeutics within the Autoantibody disease area.
Jen also provides leadership to global commercial teams to establish effective partnerships with cross-functional and regional stakeholders to ensure launch readiness for new products, and to maximize current in-market assets worldwide.
Before joining Janssen in 2020 as part of the Johnson & Johnson acquisition of Momenta Pharmaceuticals, Jen served as the Vice President of Commercial leading commercial strategy and execution at Momenta developing novel medicines for rare disease patients. In this role, Jen also led the integration of Momenta into the Johnson & Johnson global commercial strategy organization.
Prior to Momenta, Jen served as President of the U.S. commercial business at Novelion Therapeutics where she was responsible for relaunching the commercial portfolio of rare ultra-orphan disease products. Jen’s team led was responsible for market access, marketing, sales, business analytics, market research, training, and partnering on business development initiatives.
Jen brings more than 20 years of commercial experience to Janssen with prior roles including WellDoc, Human Genome Sciences, Medimmune, and Ortho Biotech. She has a background in health care consulting with organizations such as The Lewin Group and Mercer. She holds an undergraduate degree from Smith College and an MBA from The Wharton School of Business at the University of Pennsylvania.
Disease Area Commercial Leader
PAMELA BRADT, M.D.
Pamela Bradt, M.D., is Vice President, Head of Data Science for the Immunology Therapeutic Area (TA) at Janssen Research & Development, LLC. In this role, Pam is responsible for driving Data Science strategy, priorities, and adoption, to build industry-leading expertise and inform key aspects of drug discovery and development, including clinical trial design, pipeline decision-making, target identification and target validation.
Pam brings multi-faceted expertise in clinical drug development, epidemiology, and health economics, having held leadership roles in both large and midsize global pharmaceutical companies. Before joining Janssen in 2021, Pam served as Chief Scientific Officer at the Institute for Clinical and Economic Review (ICER), where she led the organization’s research enterprise, including systematic evidence reviews and health economic modeling.
Prior to her role at ICER, Pam served as Chief Medical Officer for Aegerion Pharmaceuticals, a biopharmaceutical company focused on rare diseases, leading Global Clinical Development, Medical Affairs and Global Health Economics and Outcomes Research (HECOR) for several therapeutic areas.
A pediatrician by training, Pam earned her medical degree from the University of Kansas School of Medicine, and her master’s degree from the University of Texas School of Public Health. Prior to joining industry, Pam worked in academic medicine, where she was nominated as Physician of the Year in Houston, Texas.
Pamela Bradt, M.D.
DAN CUA, PH.D.
PATHWAY AREA LEADER, IL-23
Dan Cua, Ph.D. is Vice President, IL-23 Pathway Area Leader for the Immunology Therapeutic Area at Janssen Research & Development, LLC. In this role, Dan oversees the design and implementation of the scientific strategy for Discovery, Early and Late clinical Development of Janssen’s IL-23 pathway program.
Prior to Janssen, Dan served as a Senior Principal Scientist at Merck research laboratory in Palo Alto, California leading the Immunology and Immuno-Oncology Discovery groups, as well as novel research programs. Prior to Merck, Dan held roles of increasing responsibility with Schering-Plough Biopharma.
Dan is a recognized leader in the field of IL-23 biology. He has published more than 100 peer-reviewed articles, including the first publication on IL-23 regulation of immunity. His articles have been cited more 41,000 times, making him one of the most cited authors in the Immunology field. In addition, he holds 15 patents.
Dan received his Ph.D. in Molecular Microbiology and Immunology from the University of Southern California (USC) School of Medicine. He also completed two postdoctoral fellowships at the USC Department of Neurobiology within the School of Medicine and DNAX Research Institute.
Dan Cua, Ph.D.
Pathway Area Leader, IL-23
Paul Duncan is Senior Director, External Innovation for the Immunology Global Commercial Strategy Organization of Janssen Global Services. In this role, Paul is responsible for leading the overall external innovation strategy and operations for Janssen Immunology, partnering closely with the Immunology Research & Development and New Business Development teams.
During his 28-year tenure with Johnson & Johnson, Paul has made significant contributions across a number of therapeutic areas and brings extensive commercial experience to his role. Prior to his current role, Paul served as the National Sales Director, Rheumatology, where under his leadership, the Rheumatology franchise successfully launched SIMPONI ARIA® (golimumab) and STELARA® (ustekinumab), while navigating the challenges of managing a portfolio and accelerating the performance of growth assets in a complex access environment. Paul played a key role in the advancement of the Janssen customer engagement model, integrating real world evidence, quality, and outcomes-based data. In addition, he led the harmonization of the Janssen sales competency model and contributed to the evolution of the strategic talent approach across Janssen North America.
Prior to his leadership in Sales, Paul was a Group Product Director supporting the Rheumatology franchise where he led the Professional Marketing effort. During his tenure, SIMPONI® (golimumab) experienced market leading growth in the anti-TNF category. Additionally, he was Regional Marketing Leader, Asia Pacific within the anti-infective and urology franchises, where he led the successful launch of DORIBAX® (doripenem) in eight countries and PRILIGY (dapoxetine) in two countries. Paul has held positions of increasing responsibility in marketing and has a long track record of success as a sales leader with previous experience as both a District Manager and Region Business Director for Janssen.
Paul earned a B.A. in Chemistry and a B.S. in Biochemistry from North Carolina State University and an MBA from Virginia Commonwealth University in Richmond, Virginia.
ALYSSA JOHNSEN, M.D., PH.D.
RHEUMATOLOGY DISEASE AREA LEADER
Alyssa Johnsen, M.D., Ph.D., is Vice President and Rheumatology/Autoimmunity Disease Area Leader for the Immunology Therapeutic Area at Janssen Research & Development, LLC. In this role, Alyssa is responsible for driving scientific leadership in rheumatology and related immune-mediated conditions, overseeing innovative compounds across multiple phases of development.
Prior to her role at Janssen, Alyssa held clinical development, translational and portfolio leadership roles across Immunology and Oncology at Bristol-Myers Squibb, encompassing both early and late development. She led development of a portfolio of immune-oncology assets from Phase 1 through POC as well as early registrational trials. Within Immunology, she held a variety of roles including leader of the translational team for a key marketed asset and the leader of the late-phase clinical development group.
Earlier in her career, Alyssa was a faculty member in the Division of Rheumatology at the Brigham and Women’s Hospital and subsequently the University of Pennsylvania, performing basic and translational research in autoimmune diseases as well as caring for rheumatology patients.
Alyssa received her bachelor’s degree in chemistry at Duke University and her Ph.D. in immunology and M.D. at Case Western Reserve University. She completed residency training in internal medicine at the Massachusetts General Hospital and a fellowship in Rheumatology at the Brigham and Women’s Hospital.
Alyssa Johnsen, M.D., Ph.D.
Rheumatology Disease Area Leader
DISEASE AREA COMMERCIAL LEADER
RHEUMATOLOGY & IMMUNODERMATOLOGY
June Lanoue is Vice President, Disease Area Commercial Leader Rheumatology & Immunodermatology for the Immunology Therapeutic Area at Janssen Global Services. In this role, she is responsible for developing and executing the commercial strategy to support the discovery, development, and launch of new therapeutics within the Rheumatology and Immunodermatology disease areas. This involves leading a team of global commercial strategy and analytics professionals to evolve deep insights to inform differentiated development plans and lifecycle management approaches.
June also provides leadership to global commercial teams to establish effective partnerships with cross-functional and regional stakeholders to ensure worldwide launch readiness for new products and line extensions, and to maximize current in-market assets worldwide.
Prior to this role, June served as the Director of Marketing for DARZALEX® (daratumumab) in the U.S. Oncology organization at Janssen. There she was responsible for leading a team to deliver strong growth, leveraging rapidly approaching line extensions for DARZALEX® for newly diagnosed multiple myeloma and launching DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj). Prior to the role, June was the National Sales Direction for CVM leading a team of approximately 400 field force.
Prior to joining Janssen in July of 2016, June spent 16 years with Novartis where she led teams to deliver strong results across multiple challenging and complex market spaces including immunology, rare inflammatory diseases, transplant, asthma, dermatology, cardiovascular and diabetes. Overall, she has led more than 15 launches across therapeutic areas.
June graduated from the State University at Binghamton, New York, with a Bachelor of Arts in Comparative Literature.
Disease Area Commercial Leader
Rheumatology & Immunodermatology
PASCALE MARTY-ETHGEN, PHARM.D., PH.D.
PORTFOLIO MANAGEMENT AND EXTERNAL INNOVATION
Pascale Marty-Ethgen, Pharm.D., Ph.D. is Vice President, Immunology Therapeutic Area Portfolio Management and External Innovation Leader for Janssen Research & Development, LLC. In this role, Pascale is responsible for implementation of the Immunology portfolio strategy, and for all aspects of portfolio management. She also leads the development and implementation of the external innovation strategy, ensuring that Janssen Immunology has access to cutting-edge, transformational external innovation, while promoting excellence in the evaluation of external assets and oversight of alliance management for the pre-clinical external portfolio.
Pascale joined Janssen in January 2015 as Vice President, Compound Development Team Leader for STELARA® (ustekinumab) where she had accountability for all research & development and lifecycle management activities for the drug. Most notably, Pascale led the team that delivered the global submission and approval in two new indications, as well as the progression of a third indication to a global Phase 3 program.
Pascale has more than 25 years of experience in the pharmaceutical industry in roles spanning portfolio strategy, commercial strategy, research & development and business development in biotechnology, consulting and multi-national companies in France, the United Kingdom and the United States. She has a proven track record of leading global, matrixed teams developing new medicines through to product registration and launch. She also possesses extensive business development experience, including due diligence and management of strategic alliances and virtual drug discovery partnerships.
Prior to joining Janssen, Pascale spent 12 years at GlaxoSmithKline where she held several positions of increasing responsibility across a broad range of therapeutic areas.
Pascale received her Pharm.D. from the University of Bordeaux, France, and her Ph.D. in Pharmacology from the University of Marseille, France.
Pascale Marty-Ethgen, Pharm.D., Ph.D.
Portfolio Management and External Innovation
LLOYD S. MILLER, M.D., PH.D.
IMMUNODERMATOLOGY DISEASE AREA LEADER
Lloyd S. Miller, M.D., Ph.D., is Vice President, Immunodermatology Disease Area Leader for the Immunology Therapeutic Area at Janssen Research & Development, LLC. In this role, Lloyd drives the development and implementation of the scientific strategy for immunodermatology to help meet the needs of the millions of patients living with immune-mediated skin diseases.
Prior to Janssen, Lloyd served as Vice Chair for Research in Dermatology within the Department of Dermatology at Johns Hopkins. He was also a Professor of Dermatology, Infectious Diseases, Orthopedic Surgery and Materials Science and Engineering at the Johns Hopkins University School of Medicine.
A known leader in dermatology, Lloyd has published more than 100 peer-reviewed manuscripts, review articles, book chapters and editorials and has given over 75 oral presentations at national and international scientific programs and meetings. Lloyd has received several grants from the National Institutes of Health (NIH), in addition to private foundation and industry funding for his research.
Lloyd received his M.D. and Ph.D. from the State University of New York Downstate Medical Center in Brooklyn, New York. He completed his dermatology residency and post-doctoral research fellowship in the Specialty Training and Advanced Research program at the University of California Los Angeles.
Lloyd S. Miller, M.D., Ph.D.
Immunodermatology Disease Area Leader
NEELY MOZAFFARIAN, M.D., PH.D.
Neely Mozaffarian, M.D., Ph.D., is Vice President Autoantibody Pathway Area Stronghold for the Immunology Therapeutic Area at Janssen Research & Development, LLC. In this role, Neely is responsible for the design and implementation of the scientific strategy for the Autoantibody Pathway portfolio, partnering with teams across the Janssen therapeutic area to identify external opportunities and platforms required for next-generation approaches to the Autoantibody Pathway targets.
Prior to her role at Janssen, Neely led a team in global clinical drug development for small and large molecules and was responsible for strategy and deliverables for autoimmunity and rheumatology programs as Senior Vice President at Ichnos Sciences, a subsidiary of Glenmark Sciences.
Prior to joining Ichnos, Neely served as Group Leader, Global Autoimmunity and Rheumatology Clinical Research and as Executive Director, Clinical Research, Inflammation and Respiratory Therapeutics at Gilead Sciences. Before joining Gilead, she held positions focusing on rheumatology and immunology at Lilly, AbbVie and Bristol Myers Squibb.
Neely earned her M.D. and Ph.D. degrees from Albert Einstein College of Medicine in New York. She trained in Internal Medicine and Rheumatology at the University of Washington, Seattle and has authored numerous abstracts and scientific articles.
Neely Mozaffarian, M.D., Ph.D.
Dan Pettitt is Vice President, Market Access, Immunology for the Global Commercial Strategy Organization, Janssen Global Services. He is responsible for developing product access strategies and corresponding evidence generation programs to optimize utilization and revenue. For more than seven years, Dan and the Immunology Access team have successfully secured access and exceeded time to reimbursement metrics for STELARA® (ustekinumab), SIMPONI® (golimumab) and TREMFYA® (guselkumab) in multiple indications.
Prior to working at Janssen, Dan spent 15 years in market access and reimbursement at Bristol-Meyers Squibb (BMS), Pfizer, and Amgen. While working at BMS, Dan led access and health economic activities for three top-selling drugs. After BMS, Dan led reimbursement activities for 10 years at Pfizer and helped his organization to win multiple U.S. managed care best partner awards. Dan was also a key contributor to a real-world evidence generation program that was able to successfully differentiate the company’s lead anti-inflammatory treatment from its competitor to prevent license removal.
Dan’s professional objectives and career aspirations have played a key role in developing viable business models and strategies that will endure as healthcare systems evolve globally. He has a strong background in commercial, clinical development, evidence-based medicine, epidemiology, and health economic disciplines. In addition, he has extensive relationships with academia and an impactful academic publication history.
Dan earned his MBA from Columbia University and a M.S. in Epidemiology and D.V.M. from the University of Guelph.
MICHAEL PLOTNICK, M.D.
GLOBAL MEDICAL AFFAIRS
Michael Plotnick, M.D. is Vice President, Global Medical Affairs for the Immunology Global Commercial Strategy Organization of Janssen Global Services. In this role, he leads a team of Global Medical Affairs leaders responsible for the clinical-commercial optimization of product development and life cycle management strategies and plans for both approved products, and products in clinical development for the industry-leading Janssen Immunology portfolio.
Michael joined Janssen in 2004 where he served as the Medical Director for the Dermatology disease area stronghold supporting the launch of REMICADE® (infliximab) for psoriatic arthritis and psoriasis in the United States. Most recently, Michael served as the Global Medical Affairs Leader for STELARA® (ustekinumab) and TREMFYA® (guselkumab).
Prior to joining Janssen, Michael served on the medical faculty of the University of Pennsylvania School of Medicine for 11 years. He was an attending physician at the Hospital of the University of Pennsylvania and Philadelphia Veterans Administration Hospital and ran a National Institutes of Health-funded laboratory studying the structure-function, kinetics and molecular mechanisms of serine protease inhibitors and their interaction with serine proteases.
Michael earned his M.D. from the New York University School of Medicine in New York City. He completed his residency training in Internal Medicine at Columbia Presbyterian Medical Center in New York City, and clinical and research fellowship training in Pulmonary and Critical Care Medicine at the University of Pennsylvania in Philadelphia, Pennsylvania.
Michael Plotnick, M.D.
Global Medical Affairs
JENNIFER E. TOWNE, PH.D.
Jennifer E. Towne, Ph.D. is Vice President, Immunology Discovery at Janssen Research & Development, where she applies her scientific expertise to generate an industry-leading Discovery and Early Development Immunology portfolio. Her oversight spans rheumatology, gastroenterology, and interleukin (IL)-23-related diseases, as well as the scientific pillars of innate and adaptive immunity and tissue mechanisms.
In her previous role at Janssen Research & Development, Jennifer was responsible for Discovery efforts in inflammatory bowel disease (IBD) on the West Coast and, shortly after, took over global responsibility for IBD Discovery.
Prior to joining Janssen, Jennifer served in various roles at Amgen where she led the development and implementation of Amgen’s IBD research strategy. She has extensive expertise in the IL-23, IL-17 and IL-1 family of proteins and has supervised both large and small molecule programs in both IBD and psoriasis.
Jennifer completed her doctoral degree in the Department of Molecular Genetics, Biochemistry, and Microbiology at the University of Cincinnati School of Medicine. She completed her post-doctoral fellowship at Immunex where she investigated the role of novel IL-1 family members in physiology and pathophysiology.
Jennifer E. Towne, Ph.D.
JOHAN L. J. VERBEECK, D.V.M., MS.c
Johan Verbeeck, D.V.M., M.Sc., is Vice President, Business Development, Immunology for Johnson & Johnson Innovation, Janssen Business Development. In this role, he leads all business development activities for the Immunology Therapeutic Area and is responsible for transactions, acquisitions, scientific licensing and alliance management.
Johan brings extensive experience in licensing and external partnering to his position, which includes the identification, evaluation and successful completion of the partnership with Protagonist Therapeutics for its oral IL-23 inhibitor, and Theravance for its GI-restricted JAK inhibitor. In 1996, he joined Johnson & Johnson through Janssen Pharmaceutica in Belgium, where he worked in the Department of Animal Health and subsequently worked in Toxicology, where he became a Study Director for a multitude of small molecule development projects.
In 2005, Johan joined Tibotec, as Lead Toxicologist for the development of the company’s first two approved anti-HIV drugs. At the same time, he was Preclinical Development Leader for the first new drug in development for tuberculosis in over 40 years. For the latter program, he received the Johnson & Johnson Medal for Research and Development in 2013. In 2007, Johan became Head of Toxicology Sciences for Janssen Research & Development. He also served as Alliance Manager in the External Alliances and Business Models group.
Johan earned his D.V.M. at the University of Ghent in Belgium and his M.Sc. in Applied Toxicology at the University of Surrey in the UK. Test
Johan L. J. Verbeeck, D.V.M.
GEORGE VRATSANOS, M.D.
TRANSLATIONAL SCIENCE AND MEDICINE
George Vratsanos, M.D. is Vice President, Translational Science and Medicine (TSM) for the Immunology Therapeutic Area at Janssen Research & Development, LLC. In this role, he is responsible for leading the TSM team, integrating closely with both Discovery and Clinical Development, and fostering new ideas and methodologies that deliver on the Janssen portfolio strategy.
In his previous role, George served as Vice President, Head of the Rheumatology/Autoimmunity Disease Area, leading a cross-functional team of experts to outline prioritized scientific and business strategies with the goal of maintaining industry leadership in rheumatology and aligning with the therapeutic area’s pathways-based approach. Prior to this, George was Head of Early Development, Immunology, where he innovated clinical trial operations and piloted external partnerships with academic networks and clinical research organizations.
Prior to joining Janssen, George served as Executive Global Program Head of the Immunology and Dermatology franchises at Novartis where he supported multiple biologic global submissions. Before that, George led Roche’s clinical development in autoimmune diseases as the Translational Medicine Leader and served as the Group Director at BMS.
A rheumatologist by training, George earned his M.D. from New York University and completed a post-doctoral fellowship in Rheumatology/Immunology at Yale University. In addition, he holds a B.S. and an M.S. in Biomedical Engineering from Columbia University.
George Vratsanos, M.D.
Translational Science and Medicine
JAN WEHKAMP, M.D.
DISEASE AREA LEADER
Jan Wehkamp, M.D. is Vice President and Gastroenterology Disease Area Leader for the Immunology Therapeutic Area at Janssen Research & Development, LLC. In this role, he is responsible for driving scientific leadership in gastroenterology for many of Janssen’s active development programs including STELARA® (ustekinumab) and TREMFYA® (guselkumab) as well as many innovative compounds in early development.
Prior to his role at Janssen, Jan served as a Heisenberg professor of medicine, teaching innate immunology in inflammation and infection at the University of Tübingen in Baden-Württemberg, Germany. In addition, he was the Chief Scientific Officer for Defensin Therapeutics, a Danish biopharmaceutical company he cofounded in 2013, that is focused on developing and commercializing products for diseases associated with dysregulation of the human microbiota. The company’s research is based on more than two decades expertise coming from Jan’s laboratory at the University of Tübingen.
Prior to this, Jan worked as a Principal Investigator of Research in Gastroenterology and Pharmacology at the Dr. Margarete-Fischer-Bosch-Institute of Clinical Pharmacology in Germany.
Jan has authored more than 120 publications and key presentations.
He received his M.D. from University of Lübeck in Germany and completed his post-doctoral work in Immunology & Microbiology at the Cleveland Clinic in Ohio and University of California in Davis, California.
Jan Wehkamp, M.D.
Disease Area Leader
NEWMAN YEILDING, M.D.
HEAD OF DEVELOPMENT
Newman Yeilding, M.D. is Head of Immunology Development at Janssen Research & Development, LLC. In this position, he is responsible for providing scientific and management leadership of global development initiatives and investments. This includes overseeing all programs supporting new molecular entities in rheumatologic, gastrointestinal, and dermatologic diseases, and the IL-23 pathway stronghold, as well as lifecycle indications for the industry-leading Janssen Immunology portfolio.
Newman joined the Janssen Pharmaceutical Companies of Johnson & Johnson through Centocor in 2002 where he served in various roles of increasing responsibility in Medical Affairs and Immunology Development. Most notably, he was instrumental in the development and approval of one of the company’s leading biologics, which he has continued to oversee through new indications in dermatology and gastroenterology. Newman has more than 25 years of clinical and research experience and has contributed to more than 30 scientific publications.
Newman earned his medical degree from the University of Alabama School of Medicine and completed his residency training in internal medicine at the Hospital of the University of Pennsylvania. He completed sub-specialty training in hematology and medical oncology and in 1995 joined the faculty at the University of Pennsylvania, where he practiced and ran a research lab focused on molecular oncology.